Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ulf Schulze Topphoff"'
Autor:
Tjalf Ziemssen, Holger Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Christoph Lassek, Stephan Schmidt, Benjamin Ettle, Ulf Schulze-Topphoff
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background: Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing–remitting multiple sclerosis (RRMS).Objectives: The objective was to describe the effectiveness of fingolimod in young adults compared to o
Externí odkaz:
https://doaj.org/article/b252bcf66d554500b9f3b23e910b99a2
Autor:
Riley Bove, Maria Pia Amato, Ruth Dobson, Kristen M. Krysko, Sharon Stoll, Sandra Vukusic, Bassem Yamout, Ronald Zielman, Swetha Krishna Gummuluri, Valentine Jehl, Ulf Schulze Topphoff, Roseanne Sullivan, Simone Fantaccini, Kerstin Hellwig
Publikováno v:
Tuesday, April 25.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfc1ac481acd9fd9c211a1fb98dd23fa
https://doi.org/10.1212/wnl.0000000000202940
https://doi.org/10.1212/wnl.0000000000202940
Autor:
Tjalf, Ziemssen, Michael, Lang, Stephan, Schmidt, Holger, Albrecht, Luisa, Klotz, Judith, Haas, Christoph, Lassek, Stefan, Lang, Veronika E, Winkelmann, Benjamin, Ettle, Ulf, Schulze-Topphoff
Publikováno v:
Journal of neurology. 269(6)
To evaluate the 5-year real-world benefit-risk profile of fingolimod in patients with relapsing-remitting MS (RRMS) in Germany.Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA) is a non-interventional real-world study to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ffdfd2546d4d262915b924418d6e60b
https://pubmed.ncbi.nlm.nih.gov/34982201
https://pubmed.ncbi.nlm.nih.gov/34982201
Autor:
Ulf Schulze-Topphoff, Tjalf Ziemssen
Publikováno v:
Journal of Personalized Medicine
Volume 11
Issue 6
Journal of Personalized Medicine, Vol 11, Iss 561, p 561 (2021)
Volume 11
Issue 6
Journal of Personalized Medicine, Vol 11, Iss 561, p 561 (2021)
(1) Background: Fingolimod (Gilenya®) was the first oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Since its approval, the treatment landscape has changed enormously. (2) Methods: Data of PANGAEA and PANGAEA 2.0, two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34bd7602b1b9c9996b76c440b9b401b
https://pubmed.ncbi.nlm.nih.gov/34208513
https://pubmed.ncbi.nlm.nih.gov/34208513
Autor:
Judith Haas, Luisa Klotz, Benjamin Ettle, Christoph Lassek, Michael Lang, Tjalf Ziemssen, Stephan Schmidt, Ulf Schulze-Topphoff, Holger Albrecht
Publikováno v:
Frontiers in Neurology
Frontiers in Neurology, Vol 12 (2021)
Frontiers in Neurology, Vol 12 (2021)
Background: Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing–remitting multiple sclerosis (RRMS).Objectives: The objective was to describe the effectiveness of fingolimod in young adults compared to o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a309f94d522b354b35a97b69ad0881
http://europepmc.org/articles/PMC7982917
http://europepmc.org/articles/PMC7982917
Autor:
Bassem Yamout, Kerstin Hellwig, Riley Bove, Pranava Katkuri, Ulf Schulze Topphoff, Dee Stoneman, Ronald Zielman, Ratnakar Pingili, Maria K. Houtchens
Publikováno v:
Multiple Sclerosis and Related Disorders. 59:103632
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef365e3999d61f0136d356c139c1937b
https://doi.org/10.1016/j.msard.2022.103632
https://doi.org/10.1016/j.msard.2022.103632
Autor:
Ulf Schulze-Topphoff, Aparna Shetty, Michel Varrin-Doyer, Nicolas Molnarfi, Sharon A Sagan, Raymond A Sobel, Patricia A Nelson, Scott S Zamvil
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e33797 (2012)
Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we examined how l
Externí odkaz:
https://doaj.org/article/dab18e5d9e7142baac8776b4aae41eb4
Autor:
Patrick, Zeni, Eva, Doepker, Ulf, Schulze-Topphoff, Ulf, Schulze Topphoff, Sabine, Huewel, Tobias, Tenenbaum, Hans-Joachim, Galla
Publikováno v:
American Journal of Physiology-Cell Physiology. 293:C855-C864
The epithelial cells of the choroid plexus separate the central nervous system from the blood forming the blood-cerebrospinal fluid (CSF) barrier. The choroid plexus is the main source of CSF, whose composition is markedly changed during pathological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3825de351546be4592a8abea4b7149
https://doi.org/10.1152/ajpcell.00470.2006
https://doi.org/10.1152/ajpcell.00470.2006
Autor:
Raymond A. Sobel, Collin M. Spencer, Brian T. Wipke, Ulf Schulze-Topphoff, Bruce A.C. Cree, Michel Varrin-Doyer, Lawrence Steinman, Robert H. Scannevin, Scott S. Zamvil, Aparna Shetty, Sharon A. Sagan, Kara Pekarek
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, vol 113, iss 17
Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid ester (FAE) that was advanced as a multiple sclerosis (MS) therapy largely for potential neuroprotection as it was recognized that FAEs are capable of activating the antioxidative transcrip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60124a8ddd90bbb8b1439b457b50318
https://pubmed.ncbi.nlm.nih.gov/27078105
https://pubmed.ncbi.nlm.nih.gov/27078105